CareDx, Inc. regulatory filings document the public-company record for a Nasdaq-listed precision medicine company serving transplant patients and caregivers. The company’s 8-K and proxy materials cover operating and financial results for testing services, patient and digital solutions, laboratory products, and clinical or regulatory disclosures tied to non-invasive molecular testing for organ transplantation.
CareDx filings also address material agreements, capital-structure matters for its common stock, shareholder voting items, board governance, executive compensation, inducement and other equity awards, and officer-role changes. Other-event disclosures include governance and legal-contingency materials, including shareholder derivative litigation settlement documents when filed.
CareDx, Inc. director Christine Cournoyer sold 16,000 shares of common stock on 2026-08-04 in open-market transactions under a Rule 10b5-1 trading plan. The weighted average sale price was $46.9358 per share, within a $46.25–$47.2250 range, leaving her with 42,943 shares held directly.
CareDx, Inc. reports that Secretary and General Counsel Jeffrey Adam Novack sold a total of 2,688 shares of common stock on August 5, 2026, in open-market or private transactions pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2025. The sales comprised 2,188 shares at a weighted average price of $46.1492 (range $45.49–$46.45) and 500 shares at $46.75 (range $46.59–$46.94).
CareDx, Inc. director Michael Goldberg reported selling 44,700 shares of Common Stock on August 4, 2026 at an average price of $47.0581 per share. After the sale he holds 61,738 shares directly and 91,045 shares indirectly through the Cavallo Trust, where he and his spouse are trustees.
A Form 144 notice for CDNA reports a proposed sale of up to 46,963 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $2,178,945.34 as of 08/05/2026. The planned sales relate to restricted stock grants of 3,268 and 10,570 shares and a stock option exercise covering 33,125 shares. The notice also lists that Peter Maag sold 75,653 shares of common stock for $3,576,851.19 on 08/04/2026 within the prior three months.
CareDx, Inc. reported that Secretary and General Counsel Jeffrey Adam Novack had 2,872 shares of common stock withheld on August 1, 2026 at $47.85 per share to satisfy tax withholding obligations related to vesting restricted stock units. After this disposition, he directly holds 108,763 shares of CareDx common stock.
CareDx, Inc. filed a notice relating to a proposed sale of its common stock through Goldman Sachs & Co. LLC. The filing indicates a planned sale of 16,000 shares, with an aggregate market value of $753,440, on or about 08/04/2026 on NASD.
The securities to be sold were acquired from the issuer as compensation in the form of Restricted Stock Units, including awards dated 06/14/2025 for 10,570 shares and 03/07/2025 for 5,430 shares. The issuer’s common shares outstanding are listed as 51,734,223.
The filing reports a proposed sale of up to 44,700 shares of CDNA common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, to be effected on or after August 4, 2026 on NASDAQ, with an aggregate market value of $2,103,497.07. The shares are shown as originating from multiple grants of restricted stock vesting under a registered compensation plan, with vesting dates ranging from 2014 through 2026 and described as issued by the issuer as compensation.